Dec 15, 2008 - Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced the launch in the European Union of Abraxane® Paclitaxel 5 mg/ml powder for suspension for infusion. Abraxane® is an albumin-bound nanoparticle formulation of paclitaxel. In the EU, Abraxane® is indicated for the treatment of metastatic breast cancer in patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline-containing therapy is not indicated.
The details can be read here.
No comments:
Post a Comment